DRUG
NNC0487-0111
Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
Status
Completed
Phase
Phase 1
Enrollment
29
Locations
2
Results
Not posted
Publications
0
Study summary
The study is testing a new study medicine called NNC0487-0111 for weight control in Chinese people with Body mass index (BMI) greater than or equal to (\>=) 24 kilogram per square meter (kg/m\^2). The aim of this study is to find out how safe the study medicine is and how it behaves in your body. Participants will either get NNC0487-0111 or placebo. Which treatment participants will get is decided by chance. Oral NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The study will last for about 60 days.
Interventions
DRUG
Participants will be randomized to receive NNC0487-0111 tablet orally at dose levels 1, 2, or 3.
DRUG
Participants will be randomized to receive a placebo tablet orally matched to NNC0487-0111.
Timeline
First posted
Feb 11, 2025
Study start
Feb 9, 2025
Primary completion
May 14, 2025
Study completion
May 14, 2025
Results posted
Not reported
Registry updated
Aug 20, 2025
Outcomes
Number of treatment emergent adverse events (TEAEs)
Time frame · From first NNC0487-0111 administration (Day 1) to completion of the end-of-study visit (Day 31)
Number of events
AUC0-24h,MD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to 24 hours after last multiple dose
Time frame · From pre-dose on Day 10 until Day 11
measured in hour\*nanomoles per liter (h\*nmol/L)
Cmax,MD; the maximum plasma concentration of NNC0487-0111 after last multiple dose
Time frame · From pre-dose on Day 10 to completion of the end-of-study visit (Day 31)
measured in nanomoles per liter(nmol/L)
tmax,MD; the time of maximum plasma concentration of NNC0487-0111 after last multiple dose
Time frame · From pre-dose on Day 10 to completion of the end-of-study visit (Day 31)
measured in hour (h)
Change in bodyweight
Time frame · From baseline Day 1 to Day 11
measured in percentage (%)
Change in fasting plasma glucose
Time frame · From baseline Day 1 to Day 11
measured in millimoles per liter (mmol/L)
Eligibility
Inclusion Criteria: * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. * Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent. * Body mass index (BMI) between 24.0 and 34.9 kilogram per square meter (kg/m\^2)(both inclusive), with a body weight greater than or equal to (\>=) 65.0 kilogram (kg), at screening. * Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol * Glycated haemoglobin (HbA1c) greater than or equal to (\>=) 6.5 percent (%) (48 millimoles per mole \[mmol/mol\]) at screening * Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values: * Vitamin D (25-hydroxycholecalciferol) less than (\<) 12 Nanograms per millilitre (ng/mL) (30 nanometer\[nM\]) at screening * Parathyroid hormone (PTH) outside normal range at screening * Total calcium outside normal range at screening * Amylase greater than or equal to (\>=) 2 times upper limit of normal at screening * Lipase greater than or equal to (\>=) 2 times upper limit of normal at screening * Calcitonin greater than or equal to (\>=) 50 picograms per milliliter (pg/mL) at screening
Study locations
China. Showing up to 24 locations stored in the fast local snapshot.
Jinan Central Hospital Affiliated to Shandong University
Ji'Nan, Shandong, China
Jinan Central Hospital
Ji'Nan, Shandong, China
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Novo Nordisk · Obesity · Heart Failure
Phase 3
Recruiting
5,610
2026-07
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
300
2026-07
Novo Nordisk · Obesity
Phase 3
Recruiting
1,150
2026-07
Novo Nordisk · Obesity · Knee Osteoarthritis (OA)
Phase 3
Recruiting
400
2026-07
Novo Nordisk · Obesity
Phase 3
Recruiting
600
2026-07
Novo Nordisk · Obesity · Overweight
Phase 3
Recruiting
400
2026-07
Novo Nordisk · Diabetes Mellitus · Overweight
Phase 3
Recruiting
630
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.